| Host: |
Rabbit |
| Applications: |
WB |
| Reactivity: |
Human/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-FCRL3 (18-180) is suitable for use in Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
WB 1:500-1:2000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
FCRL3 |
| Gene ID: |
115352 |
| Uniprot ID: |
FCRL3_HUMAN |
| Immunogen Region: |
18-180 |
| Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 18-180 of human FCRL3 (NP_443171.2). |
| Immunogen Sequence: |
GVAPKAVLLLNPPWSTAFKG EKVALICSSISHSLAQGDTY WYHDEKLLKIKHDKIQITEP GNYQCKTRGSSLSDAVHVEF SPDWLILQALHPVFEGDNVI LRCQGKDNKNTHQKVYYKDG KQLPNSYNLEKITVNSVSRD NSKYHCTAYRKFYILDIEVT SKP |
| Tissue Specificity | Primarily expressed in secondary lymphoid tissues by mature subsets of B-cells. Low expression on transitional B cells which increases to higher surface expression on mature and memory B-cells with innate-like features (at protein level). Expressed a low levels in naive and germinal center B-cells but also expressed in NK cells (at protein level). Expressed in unfertilized oocytes (at protein level). Expressed in a population of thymically derived naturally occurring regulatory T-cells that exhibits a memory phenotype, specialized in suppressing immune response to self-antigens. Detected in spleen, lymph node, peripheral blood lymphocytes, thymus, bone marrow, kidney, salivary gland, adrenal gland and uterus. |
| Post Translational Modifications | Phosphorylated on cytoplasmic tyrosines.required for interaction with protein tyrosine phosphatases and protein tyrosine kinases. |
| Function | Promotes TLR9-induced B-cell proliferation, activation and survival but inhibits antibody production and suppresses plasma cell differentiation. Enhances activation of NF-kappa-B and MAPK signaling pathways in TLR9 stimulated B-cells. Has inhibitory potentional on B-cell receptor (BCR)-mediated signaling, possibly through association with SH2 domain-containing phosphatases. Inhibits cell tyrosine phosphorylation, calcium mobilization and activation-induced cell death induced through BCR signaling. Regulatory T-cells expressing FCRL3 exhibit a memory phenotype, are relatively nonresponsive to antigenic stimulation in presence of IL2 and have reduced capacity to suppress the proliferation of effector T-cells. Acts as a human-specific epitope on the cell surface of oocytes (oolemma) and plays a role during sperm-egg adhesion and fusion. Interacts with the IZUMO1-IZUMO1R/JUNO sperm-egg complex and replaces IZUMO1R/JUNO as IZUMO1 receptor during fertilization, thereby permitting species-specific gamete fusion. |
| Protein Name | Fc Receptor-Like Protein 3Fcr-Like Protein 3Fcrl3Fc Receptor Homolog 3Fcrh3Ifgp Family Protein 3Hifgp3Immune Receptor Translocation-Associated Protein 3MaiaSh2 Domain-Containing Phosphatase Anchor Protein 2Cd Antigen Cd307c |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinCell ProjectionMicrovillus MembraneLocalized Along The Oolemma Microvilli Of Unfertilized Oocytes |
| Alternative Antibody Names | Anti-Fc Receptor-Like Protein 3 antibodyAnti-Fcr-Like Protein 3 antibodyAnti-Fcrl3 antibodyAnti-Fc Receptor Homolog 3 antibodyAnti-Fcrh3 antibodyAnti-Ifgp Family Protein 3 antibodyAnti-Hifgp3 antibodyAnti-Immune Receptor Translocation-Associated Protein 3 antibodyAnti-Maia antibodyAnti-Sh2 Domain-Containing Phosphatase Anchor Protein 2 antibodyAnti-Cd Antigen Cd307c antibodyAnti-FCRL3 antibodyAnti-FCRH3 antibodyAnti-IFGP3 antibodyAnti-IRTA3 antibodyAnti-SPAP2 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
